Genome-wide profiling of papillary thyroid cancer identities MUC1 as an independent prognostic marker

Cancer Research

Volumn 64, Issue 11, 2004, Pages 3780-3789

  Wreesmann, Volkert B ^a   Sieczka, Elizabeth M ^a   Socci, Nicholas D ^a   Hezel, Michael ^a   Belbin, Thomas J ^b   Childs, Geoffrey ^b   Patel, Snehal G ^a   Patel, Kepal N ^a   Tallini, Giovanni ^c   Prystowsky, Michael ^b   Shaha, Ashok R ^a   Kraus, Dennis ^a   Shah, Jalin P ^a   Rao, Pulivarthi H ^d   Ghossein, Ronald ^a   Singh, Bhuvanesh ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^c BELLARIA HOSPITAL   (Italy)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MUCIN 1;

ADULT; ARTICLE; CHROMOSOME 11Q; CHROMOSOME 13Q; CHROMOSOME 17Q; CHROMOSOME 19; CHROMOSOME 1P; CHROMOSOME 1Q; CHROMOSOME 22; CHROMOSOME 2Q; CHROMOSOME 4; CHROMOSOME 5P; CHROMOSOME 6P; CHROMOSOME 6Q; CHROMOSOME 8Q; CHROMOSOME 9Q; COMPARATIVE GENOMIC HYBRIDIZATION; DNA FINGERPRINTING; DNA MICROARRAY; FEMALE; GENE AMPLIFICATION; GENE CLUSTER; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GENETIC MARKER; GENETIC VARIABILITY; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MOLECULAR BIOLOGY; NUCLEOTIDE SEQUENCE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; SURVIVAL; THYROID PAPILLARY CARCINOMA; THYROID PAPILLARY CARCINOMA TALL CELL VARIANT; TREATMENT OUTCOME; UNINDEXED SEQUENCE; VALIDATION PROCESS;

CA-15-3 ANTIGEN; CARCINOMA, PAPILLARY; FEMALE; GENE AMPLIFICATION; GENE DOSAGE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; PROGNOSIS; REPRODUCIBILITY OF RESULTS; THYROID NEOPLASMS; UP-REGULATION;

EID: 2542632632     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-03-1460     Document Type: Article

References (64)

1. Cahill DP, Kinzler KW, Vogelstein B, Lengauer C. Genetic instability and Darwinian selection in tumours. Trends Cell Biol 1999;9:M57-60.
2. Hyman E, Kauraniemi P, Hautaniemi S, et al. Impact of DNA amplification on gene expression patterns in breast cancer. Cancer Res 2002;62:6240-5.
3. Singh B, Reddy PG, Goberdhan A, et al. p53 regulates cell survival by inhibiting PIK3CA in squamous cell carcinomas. Genes Dev 2002;16:984-93.
4. Platzer P, Upender MB, Wilson K, et al. Silence of chromosomal amplifications in colon cancer. Cancer Res 2002;62:1134-8.
5. Pollack JR, Sorlie T, Perou CM, et al. Microarray analysis reveals a major direct role of DNA copy number alteration in the transcriptional program of human breast tumors. Proc Natl Acad Sci USA 2002;99:12963-8.
6. Ross JS, Fletcher JA. The HER-2/neu oncogene: prognostic factor, predictive factor and target for therapy. Semin Cancer Biol 1999;9:125-38.
7. Arteaga CL. The epidermal growth factor receptor: from mutant oncogene in nonhuman cancers to therapeutic target in human neoplasia. J Clin Oncol 2001;19: 32S-40S.
8. Monni O, Hyman E, Mousses S, Barlund M, Kallioniemi A, Kallioniemi OP. From chromosomal alterations to target genes for therapy: integrating cytogenetic and functional genomic views of the breast cancer genome. Semin Cancer Biol 2001;11: 395-401.
9. Huang Y, Prasad M, Lemon WJ, et al. Gene expression in papillary thyroid carcinoma reveals highly consistent profiles. Proc Natl Acad Sci USA 2001;98:15044-9.
10. Hemmer S, Wasenius VM, Knuutila S, Franssila K, Joensuu H. DNA copy number changes in thyroid carcinoma. Am J Pathol 1999;154:1539-47.
11. Kjellman P, Lagercrantz S, Hoog A, Wallin G, Larsson C, Zedenius J. Gain of 1q and loss of 9q21.3-q32 are associated with a less favorable prognosis in papillary thyroid carcinoma. Genes Chromosomes Cancer 2001;32:43-9.
12. Hawk WA, Hazard JB. The many appearances of papillary carcinoma of the thyroid. Cleve Clin Q 1976;43:207-15.
13. Prendiville S, Burman KD, Ringel MD, et al. Tall cell variant: an aggressive form of papillary thyroid carcinoma. Otolaryngol Head Neck Surg 2000;122:352-7.
14. Rosai J, Carcangiu ML, DeLellis RA. Tumors of the thyroid gland. Washington, DC: Armed Forces Institute of Pathology, 1992.
15. Shaha AR, Shah JP, Loree TR. Patterns of failure in differentiated carcinoma of the thyroid based on risk groups. Head Neck 1998;20:26-30.
16. Hughes CJ, Shaha AR, Shah JP, Loree TR. Impact of lymph node metastasis in differentiated carcinoma of the thyroid: a matched-pair analysis. Head Neck 1996; 18:127-32.
17. Singh B, Gogineni SK, Sacks PG, et al. Molecular cytogenetic characterization of head and neck squamous cell carcinoma and refinement of 3q amplification. Cancer Res 2001;61:4506-13.
18. Belbin TJ, Singh B, Barber I, et al. Molecular classification of head and neck squamous cell carcinoma using cDNA microarrays. Cancer Res 2002;62:1184-90.
19. Harris TM, Childs G. Global gene expression patterns during differentiation of F9 embryonal carcinoma cells into parietal endoderm. Funct Integr Genomics 2002;2: 105-19.
20. Yang YH, Dudoit S, Luu P, et al. Normalization for cDNA microarray data: a robust composite method addressing single and multiple slide systematic variation. Nucleic Acids Res 2002;30:e15.
21. Schadt EE, Li C, Ellis B, Wong WH. Feature extraction and normalization algorithms for high-density oligonucleotide gene expression array data. J Cell Biochem Suppl 2001;37:120-5.
22. Tseng GC, Oh MK, Rohlin L, Liao JC, Wong WH. Issues in cDNA microarray analysis: quality filtering, channel normalization, models of variations and assessment of gene effects. Nucleic Acids Res 2001;29:2549-57.
23. Soukas A, Cohen P, Socci ND, Friedman JM. Leptin-specific patterns of gene expression in white adipose tissue. Genes Dev 2000;14:963-80.
24. Soukas A, Socci ND, Saatkamp BD, Novelli S, Friedman JM. Distinct transcriptional profiles of adipogenesis in vivo and in vitro. J Biol Chem 2001;276:34167-74.
25. Davison AC, Hinkley DV. Bootstrap methods and their application. Cambridge: Cambridge University Press, 1997.
26. Efron B, Tibshirani RJ. An introduction to the bootstrap. London: Chapman & Hall, 1994.
27. Felsenstein J. Confidence limits on phylogenies: an approach using the bootstrap. Evolution 1985;39:783-91.
28. Felsenstein J. Phylip (phylogeny inference package). Seattle: Department of Genetics, University of Washington, 1995.
29. Beresford GW, Boss JM. CIITA coordinates multiple histone acetylation modifications at the HLA-DRA promoter. Nat Immunol 2001;2:652-7.
30. Kitamura Y, Shimizu K, Tanaka S, Ito K, Emi M. Association of allelic loss on 1q, 4p, 7q, 9p, 9q, and 16q with postoperative death in papillary thyroid carcinoma. Clin Cancer Res 2000;6:1819-25.
31. Estilo CL, O-Charoenrat P, Ngai I, et al. The role of novel oncogenes SCCRO and PIK3CA in squamous cell carcinoma of the oral tongue. Clin Cancer Res 2003;9: 2300-6.
32. Hoos A, Cordon-Cardo C. Tissue microarray profiling of cancer specimens and cell lines: opportunities and limitations. Lab Invest 2001;81:1331-8.
33. Ho SB, Niehans GA, Lyftogt C, et al. Heterogeneity of mucin gene expression in normal and neoplastic tissues. Cancer Res 1993;53:641-51.
34. Lehmann U, Glockner S, Kleeberger W, von Wasielewski HF, Kreipe H. Detection of gene amplification in archival breast cancer specimens by laser-assisted microdissection and quantitative real-time polymerase chain reaction. Am J Pathol 2000;156: 1855-64.
35. Rahn JJ, Dabbagh L, Pasdar M, Hugh JC. The importance of MUC1 cellular localization in patients with breast carcinoma: an immunohistologic study of 71 patients and review of the literature. Cancer (Phila) 2001;91:1973-82.
36. Adsay NV, Merati K, Andea A, et al. The dichotomy in the preinvasive neoplasia to invasive carcinoma sequence in the pancreas: differential expression of MUC1 and MUC2 supports the existence of two separate pathways of carcinogenesis. Mod Pathol 2002;15:1087-95.
37. Shaha AR. Controversies in the management of thyroid nodule. Laryngoscope 2000; 110:183-93.
38. Hay ID, Thompson GB, Grant CS, et al. Papillary thyroid carcinoma managed at the Mayo Clinic during six decades (1940-1999): temporal trends in initial therapy and long-term outcome in 2444 consecutively treated patients. World J Surg 2002;26: 879-85.
39. van de Vijver MJ, He YD, van't Veer LJ, et al. A gene expression signature as a predictor of survival in breast cancer. N Engl J Med 2002;347:1999-2009.
40. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001;344:1031-7.
41. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-92.
42. Wreesmann VB, Ghossein RA, Patel SG, et al. Genome-wide appraisal of thyroid cancer progression, Am J Pathol 2002;161:1549-56.
43. Shimada H, Ichikawa H, Ohki M. Potential involvement of the AML1-MTG8 fusion protein in the granulocytic maturation characteristic of the t(8;21) acute myelogenous leukemia revealed by microarray analysis. Leukemia 2002;16:874-85.
44. Moinova HR, Chen WD, Shen L, et al. HLTF gene silencing in human colon cancer. Proc Natl Acad Sci USA 2002;99:4562-7.
45. Inaba T, Roberts WM, Shapiro LH, et al. Fusion of the leucine zipper gene HLF to the E2A gene in human acute B-lineage leukemia. Science (Wash DC) 1992;257:531-4.
46. Moon BK, Lee YJ, Battle P, Jessup JM, Raz A, Kim HR. Galectin-3 protects human breast carcinoma cells against nitric oxide-induced apoptosis: implication of galectin-3 function during metastasis. Am J Pathol 2001;159:1055-60.
47. Tsai MS, Bogart DF, Castaneda JM, Li P, Lupu R. Cyr61 promotes breast tumorigenesis and cancer progression. Oncogene 2002;21:8178-85.
48. Patel V, Aldridge K, Ensley JF, et al. Laminin-gamma2 overexpression in head-and-neck squamous cell carcinoma. Int J Cancer 2002;99:583-8.
49. Takahashi S, Hasebe T, Oda T, et al. Cytoplasmic expression of laminin gamma2 chain correlates with postoperative hepatic metastasis and poor prognosis in patients with pancreatic ductal adenocarcinoma. Cancer (Phila) 2002;94:1894-901.
50. Buyukbayram H, Arslan A. Value of tenascin-C content and association with clinicopathological parameters in uterine cervical lesions. Int J Cancer 2002; 100:719-22.
51. Herold-Mende C, Mueller MM, Bonsanto MM, Schmitt HP, Kunze S, Steiner HH. Clinical impact and functional aspects of tenascin-C expression during glioma progression. Int J Cancer 2002;98:362-9.
52. Cai M, Onoda K, Takao M, et al. Degradation of tenascin-C and activity of matrix metalloproteinase-2 are associated with tumor recurrence in early stage non-small cell lung cancer. Clin Cancer Res 2002;8:1152-6.
53. Saha S, Bardelli A, Buckhaults P, et al. A phosphatase associated with metastasis of colorectal cancer. Science (Wash DC) 2001;294:1343-6.
54. Kitamura Y, Shimizu K, Tanaka S, Ito K, Emi M. Allelotyping of anaplastic thyroid carcinoma: frequent allelic losses on 1q, 9p, 11, 17, 19p, and 22q. Genes Chromosomes Cancer 2000;27:244-51.
55. Waltz MR, Pandelidis SM, Pratt W, et al. A microsatellite within the MUC1 locus at 1q21 is altered in the neoplastic cells of breast cancer patients. Cancer Genet Cytogenet 1998;100:63-7.
56. Dyomin VG, Palanisamy N, Lloyd KO, et al. MUC1 is activated in a B-cell lymphoma by the t(1; 14)(q21;q32) translocation and is rearranged and amplified in B-cell lymphoma subsets. Blood 2000;95:2666-71.
57. McGuckin MA, Walsh MD, Hohn BG, Ward BG, Wright RG. Prognostic significance of MUC1 epithelial mucin expression in breast cancer. Hum Pathol 1995;26: 432-9.
58. Hilkens J, Ligtenberg MJ, Vos HL, Litvinov SV. Cell membrane-associated mucins and their adhesion-modulating property. Trends Biochem Sci 1992;17:359-63.
59. Agrawal B, Krantz MJ, Reddish MA, Longenecker BM. Cancer-associated MUC1 mucin inhibits human T-cell proliferation, which is reversible by IL-2. Nat Med 1998;4:43-9.
60. Bieche I, Ruffet E, Zweibaum A, Vilde F, Lidereau R, Franc B. MUC1 mucin gene, transcripts, and protein in adenomas and papillary carcinomas of the thyroid. Thyroid 1997;7:725-31.
61. Zrihan-Licht S, Weiss M, Keydar I, Wreschner DH. DNA methylation status of the MUC1 gene coding for a breast-cancer-associated protein. Int J Cancer 1995;62: 245-51.
62. Weiss M, Baruch A, Keydar I, Wreschner DH. Preoperative diagnosis of thyroid papillary carcinoma by reverse transcriptase polymerase chain reaction of the MUC1 gene. Int J Cancer 1996;66:55-9.
63. Hughes OD, Bishop MC, Perkins AC, et al. Targeting superficial bladder cancer by the intravesical administration of copper-67-labeled anti-MUC1 mucin monoclonal antibody C595. J Clin Oncol 2000;18:363-70.
64. Apostolopoulos V, Pietersz GA, McKenzie IF. MUC1 and breast cancer. Curr Opin Mol Ther 1999;1:98-103.